Ras oncogenes play an important role in carcinogenesis and are frequently found in various human tumour types. Cellular activity of Ras oncoprotein, regulated through the enzyme farnesyl transferase, is crucial in the process of ras-dependent carcinogenesis, and therefore, specific inhibition of this enzyme is an attractive goal in anticancer treatment. Specific inhibitors of farnesyl transferase have been developed in recent years, many of them showing in vitro and in vivo growth inhibitory or cytostatic activity. Recently, results of the first clinical studies with various farnesyl transferase inhibitors have been presented. In the design of phase I and II studies, either single-agent or combination studies, new endpoints have to be defined in order to properly assess feasibility, antitumour activity and clinical valuability. (C) 2000 Harcourt Publishers Ltd.

Bisubstrate inhibitors, CAAX peptidomimetics, Clinical, Farnesyl transferase inhibitors, FPP analogues, Trials
dx.doi.org/10.1053/ctrv.2000.0187, hdl.handle.net/1765/65802
Cancer Treatment Reviews
Department of Medical Oncology

Eskens, F.A.L.M, Stoter, G, & Verweij, J. (2000). Farnesyl transferase inhibitors: Current developments and future perspectives. Cancer Treatment Reviews (Vol. 26, pp. 319–332). doi:10.1053/ctrv.2000.0187